HER2 and surgery: More questions to answer

Lancet

Volumn 362, Issue 9383, 2003, Pages 502-503

  Spigel, David R ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NEU DIFFERENTIATION FACTOR; TRASTUZUMAB;

BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; NOTE; ONCOGENE NEU; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH;

EID: 0041656445     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14147-5     Document Type: Note

References (13)

1. Slamon D., Clark G., Wong S., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science. 235:1987;177-182.
2. Perou C.M., Tibshirani R., Aas T., et al. Molecular portraits of human breast tumours. Proc Natl Acad Sci USA. 98:2001;10869-10874.
3. Carlomagno C., Perrone F., Gallo C., et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 14:1996;2702-2708.
4. Berns E., Foekens J., van Staveren I.L., et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene. 159:1995;11-18.
5. Seshadri R., Firgaira F., Horsfall D., et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer: the South Australian Breast Cancer Study Group. J Clin Oncol. 11:1993;1936-1942.
6. Zemzoum I., Kates R.E., Ross J.S., et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol. 21:2003;1022-1028.
7. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20:2002;719-726.
8. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:2001;783-792.
9. Sieweke M., Bissell M. The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. Crit Rev Oncog. 5:1994;297-311.
10. Martins-Green M., Boudreau N., Bissell M. Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous sarcoma virus. Cancer Res. 54:1994;4334-4341.
11. Rowley D. What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev -99. 17:1998;411-419.
12. Hofer S., Shrayer D., Reichner J., et al. Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg. 133:1998;383-389.
13. Burstein H.J., Harris L.N., Gelman R., et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 21:2003;46-53.